Georg Feldmann1. 1. Klinik und Poliklinik für Innere Medizin III, CIO Aachen-Bonn-Köln-Düsseldorf, Universitätsklinikum Bonn, Venusberg-Campus 1, 53127, Bonn, Deutschland. georg.feldmann@uni-bonn.de.
Abstract
BACKGROUND: Pancreatic cancer is among the most fatal of all known human malignancies and novel therapeutic concepts are urgently required. OBJECTIVES: A brief overview of currently available options for systemic therapy is provided with a focus on new developments in recent years. In addition, an outlook on possible relevant trends for future advancements is given. DATA SITUATION: Although the systemic treatment of pancreatic cancer remains challenging, in recent years significant progress has been made in cytostatic chemotherapy in palliative as well as adjuvant settings. While immunotherapeutic approaches currently remain restricted to selected individual cases, the systemic molecular genetic characterization and individualized targeted therapeutic approaches are increasingly gaining in importance. CONCLUSION: Treatment of pancreatic cancer patients currently remains a domain of cytostatic chemotherapy but novel approaches are emerging that have the potential to revolutionize the therapeutic landscape of pancreatic cancer in the near future.
BACKGROUND:Pancreatic cancer is among the most fatal of all known human malignancies and novel therapeutic concepts are urgently required. OBJECTIVES: A brief overview of currently available options for systemic therapy is provided with a focus on new developments in recent years. In addition, an outlook on possible relevant trends for future advancements is given. DATA SITUATION: Although the systemic treatment of pancreatic cancer remains challenging, in recent years significant progress has been made in cytostatic chemotherapy in palliative as well as adjuvant settings. While immunotherapeutic approaches currently remain restricted to selected individual cases, the systemic molecular genetic characterization and individualized targeted therapeutic approaches are increasingly gaining in importance. CONCLUSION: Treatment of pancreatic cancerpatients currently remains a domain of cytostatic chemotherapy but novel approaches are emerging that have the potential to revolutionize the therapeutic landscape of pancreatic cancer in the near future.
Authors: Maeve A Lowery; Emmet J Jordan; Olca Basturk; Ryan N Ptashkin; Ahmet Zehir; Michael F Berger; Tanisha Leach; Brian Herbst; Gokce Askan; Hannah Maynard; Danielle Glassman; Christina Covington; Nikolaus Schultz; Ghassan K Abou-Alfa; James J Harding; David S Klimstra; Jaclyn F Hechtman; David M Hyman; Peter J Allen; William R Jarnagin; Vinod P Balachandran; Anna M Varghese; Mark A Schattner; Kenneth H Yu; Leonard B Saltz; David B Solit; Christine A Iacobuzio-Donahue; Steven D Leach; Eileen M O'Reilly Journal: Clin Cancer Res Date: 2017-07-28 Impact factor: 12.531
Authors: Daniel Ansari; Henrik Ohlsson; Carl Althini; Monika Bauden; Qimin Zhou; Dingyuan Hu; Roland Andersson Journal: Anticancer Res Date: 2019-07 Impact factor: 2.480
Authors: Malcolm J Moore; David Goldstein; John Hamm; Arie Figer; Joel R Hecht; Steven Gallinger; Heather J Au; Pawel Murawa; David Walde; Robert A Wolff; Daniel Campos; Robert Lim; Keyue Ding; Gary Clark; Theodora Voskoglou-Nomikos; Mieke Ptasynski; Wendy Parulekar Journal: J Clin Oncol Date: 2007-04-23 Impact factor: 44.544
Authors: Helmut Oettle; Peter Neuhaus; Andreas Hochhaus; Jörg Thomas Hartmann; Klaus Gellert; Karsten Ridwelski; Marco Niedergethmann; Carl Zülke; Jörg Fahlke; Michael B Arning; Marianne Sinn; Axel Hinke; Hanno Riess Journal: JAMA Date: 2013-10-09 Impact factor: 56.272
Authors: Mark Yarchoan; Melinda C Myzak; Burles A Johnson; Ana De Jesus-Acosta; Dung T Le; Elizabeth M Jaffee; Nilofer S Azad; Ross C Donehower; Lei Zheng; Paul E Oberstein; Robert L Fine; Daniel A Laheru; Michael Goggins Journal: Oncotarget Date: 2017-07-04